This is genuinely debated.
Several large studies found women with frequent, severe, or persistent hot flashes had a moderately higher rate of cardiovascular events and worse markers of vascular and brain aging than women without them. But these are observational associations, not proof that hot flashes cause the damage, and no guideline currently treats hot flashes as a formal cardiovascular risk factor or recommends treating them specifically to prevent disease. The honest takeaway: notable hot flashes are a reason to have your conventional heart risk factors checked, not yet a licensed reason to treat the flashes purely for prevention.
Position 1 does not claim hot flashes cause the damage; it claims they are a cheap, visible signal that identifies women whose vascular and brain aging deserves earlier attention. Position 2 replies that labeling most women 'at risk' on moderate observational hazard ratios risks medicalizing a normal transition with no supporting prevention trial.
What the research shows, and which source each finding rests on
In SWAN, women with frequent baseline vasomotor symptoms (6 or more days per 2 weeks) had HR 1.51 (95 percent CI 1.05-2.17) for incident cardiovascular events over 22 years; persistent frequent symptoms over time carried HR 1.77 (1.33-2.35), adjusted for risk factors
A pooled analysis of 6 prospective cohorts (n = 23,365) found severe vasomotor symptoms associated with HR 2.11 (1.62-2.76) for cardiovascular disease; night sweats specifically carried risk while hot flash frequency alone did not
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Hot flashes are a risk signal, not benign
Rebecca Thurston, Sharon Malone, Mary Claire Haver, and Lisa Mosconi
Frequent and severe hot flashes are associated with higher rates of cardiovascular events and with structural brain markers, independent of standard risk factors, in a life stage where standard risk calculators often underperform for women.
Primarily a quality-of-life symptom; risk-marker story not yet actionable
Guideline committees in effect, since no guideline treats vasomotor symptoms as a formal cardiovascular risk factor
The associations are moderate, observational, and inconsistent by symptom subtype, since hot flash frequency alone was not associated with cardiovascular disease in the pooled analysis, only severity and night sweats specifically; no interventional trial shows that treating hot flashes reduces cardiovascular events or dementia, and NICE explicitly warns hormone therapy should not be used for cardiovascular or dementia prevention.
What would settle it: A randomized trial of vasomotor symptom treatment powered for vascular or brain endpoints, or imaging surrogates like white matter hyperintensity progression, along with genetic and prospective studies using physiologic symptom measurement and adjudicated cardiovascular events.
What is really going on here
- Given my severe, early, or persistent flashes, has anyone looked at my heart? The defensible ask is a cardiovascular risk assessment, not a promise that treating flashes protects the heart, since that promise has no trial evidence behind it.
Questions for your doctor
- Given how severe or persistent my hot flashes are, should we do a cardiovascular risk assessment (blood pressure, lipids, glucose, smoking, sleep)?
- Is treating my hot flashes expected to lower my cardiovascular or dementia risk, or only to relieve the symptom itself?
- Are my hot flashes happening mostly at night, and could that be relevant to brain health markers specifically?
- What is my personal and family history of heart disease, and how does that factor into my care plan?
Questions with no answer yet
If a trial specifically treated hot flashes and measured cardiovascular events afterward, would the risk actually go down, or are hot flashes just a marker of risk that was already there for other reasons?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: No interventional evidence exists that treating hot flashes with hormone therapy, an NK antagonist, or anything else reduces cardiovascular events or dementia. The associations so far are entirely observational, and a trial of this kind would require years of follow-up in a very large sample, which is a large part of why it has not been attempted.
What would test it: A randomized trial of vasomotor symptom treatment powered for cardiovascular or brain-imaging endpoints, which does not currently exist.
Why did hot flash frequency alone show no cardiovascular association in the large pooled analysis, while severity and night sweats specifically did?
Partly studiedWhat is known: The pooled six-cohort analysis found frequency alone was not associated with cardiovascular disease, only severity and night sweats, which the skeptical position argues is the kind of inconsistency a true, uniform causal risk factor would not be expected to show.
What would test it: Research directly comparing what biologically distinguishes severe or nocturnal hot flashes from frequent but milder ones, to see whether they represent different underlying processes.
Does the white-matter-hyperintensity association hold up when hot flashes are measured only by self-report, or does it require the more burdensome objective, physiologic monitoring used in the positive studies?
Partly studiedWhat is known: An earlier pilot study found the white matter hyperintensity association held for physiologically monitored sleep hot flashes but not for self-report, suggesting measurement method itself may explain some inconsistency across studies.
What would test it: A study directly comparing self-reported and objectively monitored hot flashes against brain imaging outcomes in the same women, to isolate the effect of measurement method.
Sources
- 1.Menopausal Vasomotor Symptoms and Risk of Incident Cardiovascular Disease Events in SWAN.Thurston RC et al., J Am Heart Assoc 2021 · Observational study
- 2.Vasomotor menopausal symptoms and risk of cardiovascular disease: a pooled analysis of six prospective studies.Zhu D et al., Am J Obstet Gynecol 2020 · Systematic review or guideline
- 3.Menopausal Vasomotor Symptoms and White Matter Hyperintensities in Midlife Women.Thurston RC et al., Neurology 2023 · Comparative or small study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- How long do hot flashes actually last?
- What actually causes a hot flash in my body?
- What is fezolinetant (Veozah) and is it safe to take for hot flashes?
- What is elinzanetant (Lynkuet) and how is it different from fezolinetant?
- Are the new non-hormonal drugs (fezolinetant, elinzanetant) as good as hormone therapy for hot flashes?
- How do I know if a hot flash treatment actually works, versus me just wanting it to work?
- Back to topic: Hot flashes and their treatments